References of "Hanson, Julien"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailProgress in the field of GPIIb/IIIa antagonists
Hanson, Julien ULg; De Leval, X.; David, Jean-Louis ULg et al

in Current Medicinal Chemistry - Cardiovascular and Hematological Agents (2004), 2

Detailed reference viewed: 17 (1 ULg)
Full Text
Peer Reviewed
See detailPharmacological characterization of N-tert-butyl-N’-[2-(4’-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time
Dogné, Jean-Michel ULg; Hanson, Julien ULg; De leval, X. et al

in Journal of Pharmacology and Experimental Therapeutics (The) (2004), 309(2), 498-505

The present study was undertaken to characterize the antiplatelet and antithrombotic effects of BM-573 [N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl] urea], an original combined ... [more ▼]

The present study was undertaken to characterize the antiplatelet and antithrombotic effects of BM-573 [N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl] urea], an original combined thromboxane receptor antagonist and thromboxane synthase inhibitor in rats, and to determine its effects on mice bleeding time. Intraperitoneal injection of a single dose of 5 mg/kg BM-573 to rats inhibited U-46619 (9,11-dideoxy-9,11-methanoepoxy-prostaglandin F-2)-induced washed platelet aggregation 30 min and 1, 2, and 4 h after drug administration with a maximum antiplatelet effect observed after 1 and 2 h. In a rat model of thrombosis induced by ferric chloride application on the abdominal aorta, BM-573 significantly reduced the thrombus weight by 92.53, 80.20, 64.75, and 18.21% at doses of 5, 2, 0.5, and 0.2 mg/kg, respectively. Time to occlusion of abdominal aorta in the BM-573-treated group (41.50+/-5.21 min) was significantly prolonged compared with the vehicle-treated rats (16.16+/-0.79 min). Like furegrelate, seratrodast, and acetylsalicylic acid, BM-573 did not affect the tail bleeding time induced by tail transection in mice compared with vehicle-treated mice. Moreover, BM-573, a close derivative of the loop diuretic torasemide, failed to induce a significant increase in diuresis in rat and did not produce a decrease in blood glucose concentration as observed with the sulfonylurea glibenclamide. In conclusion, we have demonstrated that the nitrobenzenic sulfonylurea BM-573, an original combined thromboxane receptor antagonist and thromboxane synthase inhibitor, is a potent antithrombotic agent that does not affect bleeding time. Moreover, BM-573 lost the diuretic property of torasemide and has no impact on glycemia. [less ▲]

Detailed reference viewed: 57 (16 ULg)
Full Text
Peer Reviewed
See detailSynthésis and pharmacological evaluation of original thromboxane A2 receptor antagonists derived from BM-573
Hanson, Julien ULg; Renard, Jean-François ULg; Neven, P. et al

in Fundamental & Clinical Pharmacology (2004)

Detailed reference viewed: 10 (2 ULg)
Peer Reviewed
See detailBM-613, a new thromboxane A2 antagonist, is characterized by a preferential activity on platelet thromboxane A2 receptors
Hanson, Julien ULg; Rolin, S.; De Leval, X. et al

Poster (2003, December)

Detailed reference viewed: 7 (0 ULg)
Peer Reviewed
See detailBM-613, a new thromboxane A2 antagonist, is characterized by a preferential activity on platelet thromboxane A2 receptors
Hanson, Julien ULg; Rolin, S.; De Leval, X. et al

Poster (2003, November 22)

Detailed reference viewed: 3 (1 ULg)
Peer Reviewed
See detailPharmacological evaluation of the thromboxane A2 receptor antagonist BM-613
Hanson, Julien ULg; Rolin, S.; De Leval, X. et al

Poster (2003, May)

Detailed reference viewed: 3 (0 ULg)
Peer Reviewed
See detailSynthesis and pharmacological evaluation of BM-613, an original thromboxane A2 antagonist
Hanson, Julien ULg; Rolin, S.; De Leval, X. et al

Poster (2003, May)

Detailed reference viewed: 3 (0 ULg)
Peer Reviewed
See detailEtude de la sélectivité tissulaire d’un nouvel antagoniste des récepteurs au thromboxane A2, le BM-613
Hanson, Julien ULg; Rolin, S.; De Leval, X. et al

Poster (2003, January 31)

Detailed reference viewed: 7 (0 ULg)
Full Text
Peer Reviewed
See detailUpdate on GPIIb/IIIa antagonists
Hanson, Julien ULg; De Leval, X.; Kolh, Philippe ULg et al

in Expert Opinion on Therapeutic Patents (2003), 13

Detailed reference viewed: 8 (1 ULg)